Mubadala and Resilience partner to develop and advance biopharma manufacturing in the UAE

Mubadala and Resilience partner to develop and advance biopharma manufacturing in the UAE

- Mubadala to establish first of its kind Biopharma Manufacturing Facility in the region based in the United Arab Emirates

- Agreement to strengthen and expand the UAE’s growing life sciences ecosystem

Abu Dhabi– Mubadala Investment Company PJSC (Mubadala), an Abu Dhabi sovereign investor, and National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, have signed a deal to further advance the UAE’s life sciences ecosystem through biopharma manufacturing.

Through a development agreement, Mubadala will establish the new manufacturing facility, in which Resilience will operate and manufacture biopharmaceutical-related products out of the United Arab Emirates. The range of therapeutics will be used to treat complex diseases such as cancer, infectious diseases, and inflammatory and autoimmune disorders. The Abu Dhabi based facility will be the first Goods Manufacturing Practice (GMP) biopharma facility in the UAE as well as the first of its kind in the region to manufacture essential life sciences products for advanced biologics. Over the past two years, Mubadala has invested in multiple rounds of equity financing in Resilience.

The two parties will play to their strengths to realize their shared goals of success. As a strategic investor focused on accelerating the economic diversification of the UAE